Keros Therapeutics, Inc. KROS
10.30 USD +0.22 (+2.18%)
Regular-session close
10.30 0.00 0.00%
After hours · Nov 13, 4:26 PM ET
9.55 Day range 10.55
9.17 52-week range 21.84
- YTD
- -49.41%
- 1 year
- -40.46%
News
zacks.com New Strong Buy Stocks for November 12th PANL, CBRL, KROS, NEPH and LRN have been added to the Zacks Rank #1 (Strong Buy) List on November 12, 2026.
zacks.com Down 21% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround Keros Therapeutics (KROS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings…
benzinga.com Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis ("MF") and anemia on concurrent…
benzinga.com Keros Therapeutics Doses First Patient In Phase 2 Clinical Study Of Rinvatercept In Patients With Duchenne Muscular Dystrophy Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with…
benzinga.com Keros Therapeutics Reveals $5M Share Repurchase Authorization Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of- benzinga.com Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18 Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $20 to $18.
benzinga.com Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.34) by 8.21 percent. This is a 90.79 percent decrease over losses of…
benzinga.com Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS Trial ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of elritercept versus epoetin alfa for the treatment of anemia due to very low, low, or…
benzinga.com Keros Therapeutics Q1 EPS $(1.21) Misses $(1.02) Estimate, Sales $367.000K Miss $583.333K Estimate Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.21) per share which missed the analyst consensus estimate of $(1.02) by 18.63 percent. This is a 133.43 percent decrease over…- benzinga.com Keros Therapeutics Presents Additional Data From Its Phase 1 Clinical Study Of Rinvatercept In Health Volunteers At 2026 Muscular Dystrophy Association Clinical & Scientific Conference Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of…
- benzinga.com Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20 Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $23 to $20.
- benzinga.com CORRECTION: Keros Therapeutics Q4 EPS $(0.86) Misses $(0.60) Estimate, Sales $385.000K Miss $2.757M Estimate Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.60) by 42.62 percent. This is a 24.56 percent increase over losses…
benzinga.com Keros Therapeutics: Q4 Earnings Insights 
benzinga.com Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price Things are hog wild at Harley-Davidson; Plus, Impresoft, Keros Therapeutics and Rivalry Corp. are all itching for a deal.
benzinga.com PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday 
benzinga.com Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - benzinga.com Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at…
- benzinga.com Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses in today’s session.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 386 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 216 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 951 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 422 stocks made new 52-week lows.
- benzinga.com 50 Biggest Movers From Yesterday Gainers
- benzinga.com 31 Stocks Moving In Monday's Mid-Day Session Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 54.1% to $3.6998 after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from NASA to provide drone and rover…
- benzinga.com 20 Stocks Moving in Monday's Pre-Market Session Gainers Puhui Wealth Investment Management Co., Ltd. (NASDAQ: PHCF) rose 49% to $3.65 in pre-market trading.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday morning, 155 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday morning, 136 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday morning, 282 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday morning, 207 companies hit new 52-week lows.- benzinga.com 45 Biggest Movers From Yesterday Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares surged 44.8% to close at $6.50 on Wednesday after the company reported topline Phase 2 bone mineral density data for EB613.
- benzinga.com 31 Stocks Moving In Wednesday's Mid-Day Session Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares jumped 58% to $7.09 after the company reported topline Phase 2 bone mineral density data for EB613.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday Before 10 a.m. ET on Tuesday, 172 companies hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Monday On Monday morning, 204 companies hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday Before 10 a.m. ET on Wednesday, 185 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Monday This morning 180 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday During Tuesday's morning session, 78 stocks hit new 52-week highs.